ERIS Lifesciences Ltd

ERIS Lifesciences Ltd Share Price Today: Live Updates & Key Insights

Get insights on ERIS Lifesciences Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

ERIS Lifesciences Ltd Share Price Chart

ERIS Lifesciences Ltd Fundamentals

Traded Volume: 1,02,184

Market Cap(Cr): 22,694

Avg Traded Price 1662.49

1 Year return 21.88%

Upper Circuit 1,679.2

Lower Circuit 1,638.5

P/E TTM 55.00

P/B Ratio 31.00

Traded Value(Cr) 1702.39

EPS TTM 30.514

Book value 30.514

Dividend 0.00%

ERIS Lifesciences Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights ERIS Lifesciences Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the ERIS Lifesciences Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W +9.74%

1M +3.96%

3M -5.10%

1Y +21.88%

YTD +25.41%

ERIS Lifesciences Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights ERIS Lifesciences Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 1.42L

Day Before Yesterday 1.14L

1W Avg 87983.80

1M Avg 84412.86

3M Avg 1.10L

ERIS Lifesciences Ltd Technical Details

ERIS Lifesciences Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 1643

Support 2 1621

Support 3 1603

Pivot Point : 1661

Resistance 1 1684

Resistance 2 1702

Resistance 3 1725

ERIS Lifesciences Ltd Corporate Actions

ERIS Lifesciences Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on ERIS Lifesciences Ltd’s capital allocation strategies.

All

Ex-Date 13-Feb-2025 Type D Description 7.35/share@735.00% Record Date 13-Feb-2025 Ratio 735.00

Ex-Date 11-Aug-2022 Type D Description 7.35/share@735.00% Record Date 16-Aug-2022 Ratio 735.00

Ex-Date 05-Aug-2021 Type D Description 6.01/share@601.00% Record Date 06-Aug-2021 Ratio 601.00

Ex-Date 13-Aug-2020 Type D Description 5.50/share@550.00% Record Date 14-Aug-2020 Ratio 550.00

Ex-Date 19-Mar-2020 Type D Description 2.87/share@287.00% Record Date 20-Mar-2020 Ratio 287.00

Ex-Date 12-Jul-2019 Type T Description /share@% Record Date - Ratio

Dividends

Announcement Date 13-Feb-2025 Ex Dividend Date 13-Feb-2025 Dividend(%) 735

Announcement Date 11-Aug-2022 Ex Dividend Date 11-Aug-2022 Dividend(%) 735

Announcement Date 05-Aug-2021 Ex Dividend Date 05-Aug-2021 Dividend(%) 601

Announcement Date 13-Aug-2020 Ex Dividend Date 13-Aug-2020 Dividend(%) 550

Announcement Date 19-Mar-2020 Ex Dividend Date 19-Mar-2020 Dividend(%) 287

Bonus

No Bonus has been declared by ERIS

Splits

No Split has been declared by ERIS

Others

Ex-Rights Date 12-Jul-2019 Premium(Rs.) Ratio

ERIS Lifesciences Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares ERIS Lifesciences Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate ERIS Lifesciences Ltd's relative performance and valuation against major competitors.

Stock Name Syngene International Ltd ₹629.25 (-0.84%) M. Cap (Cr) 253.55 1 Yr Return (%) -25.70% P/E (TTM) 54.15 PB Ratio 5.77

Stock Name Piramal Pharma Ltd ₹188.38 (-0.66%) M. Cap (Cr) 250.40 1 Yr Return (%) -23.39% P/E (TTM) -1054.76 PB Ratio 3.16

Stock Name Pfizer Ltd ₹5000.50 (-0.56%) M. Cap (Cr) 228.76 1 Yr Return (%) -2.55% P/E (TTM) 27.26 PB Ratio 5.42

Stock Name ERIS Lifesciences Ltd ₹1666.00 (-0.22%) M. Cap (Cr) 226.94 1 Yr Return (%) +21.88% P/E (TTM) 54.60 PB Ratio 8.19

Stock Name Cohance Lifesciences Ltd ₹589.30 (+1.28%) M. Cap (Cr) 225.45 1 Yr Return (%) -53.76% P/E (TTM) 90.96 PB Ratio 13.19

Stock Name Astrazeneca Pharma India Ltd ₹8988.00 (-1.59%) M. Cap (Cr) 224.70 1 Yr Return (%) +42.54% P/E (TTM) 112.83 PB Ratio 33.08

Stock Name Wockhardt Ltd ₹1311.30 (-1.04%) M. Cap (Cr) 213.08 1 Yr Return (%) +11.63% P/E (TTM) -926.42 PB Ratio 6.27

ERIS Lifesciences Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by ERIS Lifesciences Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 701.86 Mar 2024 336.29 Mar 2023 322.33 Mar 2022 369.41 Mar 2021 395.41

PARTICULARS Investing Activities Mar 2025 -358.99 Mar 2024 -2491.89 Mar 2023 -513.30 Mar 2022 -267.64 Mar 2021 -347.86

PARTICULARS Financing Activities Mar 2025 -310.46 Mar 2024 2160.06 Mar 2023 193.75 Mar 2022 -88.42 Mar 2021 -81.13

PARTICULARS Net Cash Flow Mar 2025 32.41 Mar 2024 4.45 Mar 2023 2.78 Mar 2022 13.36 Mar 2021 -33.58

ERIS Lifesciences Ltd Shareholding Pattern

This shows the ownership breakdown of ERIS Lifesciences Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 54.85%

Public 18.57%

Other Institutions 2.03%

FII 7.21%

Mutual Funds 17.33%

About ERIS Lifesciences Ltd

Eris Lifesciences Limited was incorporated on January 25, 2007. Subsequently, the name of the company was changed to 'Eris Lifesciences Private Limited' on February 9, 2007. Further, the Company was converted into a Public Limited cCompany and the name was changed to 'Eris Lifesciences Limited' on February 2, 2017. The Company has a manufacturing plant in Guwahati, Assam and is presently engaged in manufacturing and marketing of pharmaceutical products. It has presence in high growth chronic, sub chronic and acute therapeutic areas that require high intervention of specialist and super specialist doctors. The company develops, manufactures and commercializes branded pharmaceutical products in selected therapeutic areas within chronic and acute categories of the Indian Pharmaceutical Market (IPM), such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infective. Its focus has been on developing products in the chronic and acute categories which are linked to lifestyle related disorders. In 2007, the company launched 'Eris' division focused on cardiology and diabetes segment. In 2008, the company launched 'Nikkos' division focused on gastroenterology and orthopedics segment. In 2009, the company launched 'Adura' division focused on cardiology and diabetes segment. In 2011, the company launched 'Montana' division focused on gynecology and pediatrics segment. In 2012, the company launched 'Inspira' division focused on cardiology segment. In 2014, the company launched 'Victus' division focused on anti-diabetes segment. During the year, the company set up manufacturing facility at Assam. In 2015, the company launched 'Eris 2' division focused on pain management segment.In 2016, the company acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited (now, Aprica Pharmaceuticals Private Limited). During the year, the company acquired 100% of the outstanding equity shares of Aprica Healthcare Private Limited and 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited. In 2017, the Company launched the initial public offering of 28,875,000 equity shares having the face value of Re 1/- each, by raising funds aggregating to Rs 1741 Crore through an Offer for Sale in June, 2017.In October 2017, Eris Lifesciences Ltd (Eris) acquired the entire shareholding of UTH Healthcare Ltd (UTH) for an all-cash consideration of Rs 129 million. UTH is largely engaged in the segments of obesity, diabetes, gestational diabetes mellitus, maternal nutrition, and cardio-vascular diseases. The acquisition provides Eris with a portfolio of products that complement its other offerings.In December 2017, Eris Lifesciences Ltd (Eris) acquired the Indian branded formulations business of Strides Shasun Ltd (Strides) for an aggregate cash consideration of Rs 5000 crore. With this acquisition, Eris acquired the marketing and distribution rights for India for 130+ brands in the Neurology, Psychiatry, Nutraceuticals and Women Healthcare therapy areas. The Indian branded formulations business being divested by Strides had sales of Rs 181 crore for FY 2017.During the year 2018, capital expenditure amounted to Rs 242.69 million. Additionally, consideration of Rs. 5,061.52 million was paid towards business acquisition.During the year 2018, UTH Healthcare Limited and Eris Healthcare Private Limited (earlier known as Strides Healthcare Private Limited) became subsidiaries of the Company.As on March 31, 2019, the Company has 5 subsidiaries out of which 4 are wholly owned subsidiaries. During the year 2019, capital expenditure amounted to Rs 374.15 million. Additionally, consideration of Rs. 107.22 million was paid towards business acquisition.In April 2019, the Company acquired the remaining shares of Kinedex Healthcare Private Limited, thereby making it a wholly owned subsidiary. It launched new business divisions, ErisART, Nutriverse, Aspire, Oncosciences, Filix, and Allure. A newly constructed facility for soft-gel was added in the year 2019 with total production capacity of 75 mn units. An extended facility has been included for supplements and Nutraceuticals with an additional capacity of 60 mn tablets, 41 mn capsules and 4 mn sachets. In December 2019, it launched Zomelis, after acquiring the trademark from Novartis.As on March 31, 2020, the Company has 5 five wholly owned subsidiaries. During the year 2020, the Company has acquired the remaining shares of Kinedex Healthcare Private Limited, thereby making it a wholly owned subsidiary. Eris Healthcare Private Limited has incorporated subsidiary company Eris Pharmaceuticals Private Limited on 2nd, June 2020. In Q3 FY 20, the Company launched Rariset, under their in-licensing agreement with Pharmanutra S.P.A for their patent protected Sucrosomial Iron.As on March 31, 2021, the Company has 3 three wholly owned and 1 other than wholly owned subsidiaries. During the year 2021, two Companies namely Aprica Healthcare Limited and Eris Therapeutics Private Limited ceased to be subsidiaries of the Company. Eris Healthcare Private Limited, wholly owned subsidiary of the Company, had incorporated a subsidiary company Eris Pharmaceuticals PrivateLimited on 2nd June, 2020.In FY'21. the Company strengthened portfolio with Gluxit, its Dapagliozin brand in the strategically important SGLT 2 segment launched in October'20. Eritel and LNBloc maintained ranks in their respective segments and made a debut in fast-growing anti-thrombotics segment through the launch of Rivalto, Rivaroxaban offering. It fortified portfolio with the launch of ZACD, an immunity-enhancing formulation and added Bricet to its portfolio. Of the top 4 Mother Brands - Serlift, Desval ER, Sonaxa and Levroxa while Serlift, and Desval ER maintained theirranks in their respective segments.Company launched human insulin through subsidiary, Eris MJ Biopharm Ltd. In Q4 FY 22, it launched Xsulin in the forms of vials & cartridges.During the year 2023, the Company acquired 100% stake in Eris Oaknet Healthcare Private Limited in 2023. It launched Glura, a DPP4 Inhibitor. In Jan'23, it acquired 9 Derma brands from Glenmark for Rs 3,400 million and in Mar'23, it acquired 9 Cosmetology brands from Dr Reddy's for Rs 2,750 million.In 2022-23, Eris Healthcare Private Limited, a wholly owned subsidiary, demerged its Acquired Brands business to Aprica Healthcare Limited, a wholly owned subsidiary, through a Scheme of Arrangement effective December 23, 2022.In FY24, Company launched two first-in-market fixed dose combinations in Oral Anti-Diabetes, via Gliclazide + Dapagliflozin and Gliclazide + Sitagliptin in 2024. The new facility in Ahmedabad started commercial operations in March, 2023. The Company initiated Dermatology formulations manufacturing in January 2024. The Company acquired Biocon's India Branded Formulation business, thereby completing the second leg of India Injectables strategy in March, 2024. It acquired a 51% stake in Swiss Parenterals Limited, a dossier driven sterile injectable business in February, 2024.In 2025, Company acquired Eris BioNxt (formerly Chemman Labs)- a biologics drug products facility with EU-GMP readiness, capable of handling Insulins, GLP-1s, MABs, and rDNA products. Second, it acquired a 30% stake in Levim Lifetech, a Chennai-based biotechnology company focused on complex biologics and gene therapies. The launch of Liraglutide brand marked the Company's potential across the Diabetes care continuum. Further, it launched three first-in-market fixed dose combinations of Dapagliflozin in FY25.

Chairman / Executive Director / M D / Promoter

Amit Indubhushan Bakshi

Registered office 8th Floor Commerce House -IV, Prahladnagar 100 FT Road, Ahmedabad, Gujarat, 380015

FAX :91-79-30451000

Background

Incorporation Year 2007

Face Value ₹1.00

Market Lot 1

ERIS Lifesciences Ltd Latest News

VIEW MORE NEWS

FAQs on ERIS Lifesciences Ltd